


In the study, STRATTICE™ Reconstructive Tissue Matrix (RTM) provided “durable long-term outcomes in Complex AWR”¹

1. Garvey PB, Giordano SA, Baumann DP, Liu J, Butler CE. Long-term outcomes after abdominal wall reconstruction with acellular dermal matrix. *J Am Coll Surg.* 2017;224(3):341-350.

Study Setup

- Analysis sample of 191 patients, with a median follow-up of 52.9 months (range 36-104 months) and 23 different surgeons. Majority of non-human ADMs were STRATTICE™ RTM (109/169).
- Follow up for hernia recurrence was performed on all patients by physical examination and confirmed by CT scan in 88%.
- Limitations of study include retrospective nature, non-comparative and non-randomized design and the potential for selection bias.
- Study conducted at a single center — The University of Texas MD Anderson Cancer Center, Houston, TX.

Hernia recurrence rates achieved stasis in years 5 through 7 when bridged repair and human ADM patients were excluded.*



*Adapted from Garvey et al., Table 4, Fig 3 (1-hernia recurrence-free probability). The cumulative hernia recurrence rates were estimated by using the Kaplan-Meier product limit method.

Human ADM was associated with higher hernia recurrence rate

- Human ADMs and bridged repair were significantly predictive of developing a hernia recurrence.
- Use of a human ADM resulted in a hazard ratio of 3.3 (95% CI=1.3-8.5, $p=0.01$)

In the study, when STRATTICE™ RTM was used, hernia recurrence rates compared favorably to those reported in studies of synthetic mesh

- These data demonstrated that hernia recurrence rates can be even improved when a bridged repair is avoided and xenograft rather than human allograft ADM is employed.
- When ADMs, including STRATTICE™ RTM were used, infectious wound complications did not progress to more serious complications such as mesh removal, reconstruction failure and hernia recurrence.

Before use, physicians should review all risk information, which can be found in the *Instructions for Use* attached to the packaging of each STRATTICE™ Tissue Matrix. Rx only. CONTRAINDICATIONS: STRATTICE™ Tissue Matrix is derived from a porcine source and should not be used in patients with known sensitivity to porcine material, or in patients with a known sensitivity to Polysorbate 20.